Literature DB >> 27745534

Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.

Soteri Polydorou1, Stephen Ross1, Peter Coleman1, Laura Duncan1, Nichole Roxas1, Anil Thomas1, Sonia Mendoza1, Helena Hansen1.   

Abstract

OBJECTIVES: This report identifies the institutional barriers to, and benefits of, buprenorphine maintenance treatment (BMT) integration in an established hospital-based opioid treatment program (OTP).
METHODS: This case study presents the authors' experiences at the clinic, hospital, and corporation levels during efforts to integrate BMT into a hospital-based OTP in New York City and a descriptive quantitative analysis of the characteristics of hospital outpatients treated with buprenorphine from 2006 to 2013 (N=735).
RESULTS: Integration of BMT into an OTP offered patients the flexibility to transition between intensive structured care and primary care or outpatient psychiatry according to need. Main barriers encountered were regulations, clinical logistics of dispensing medications, internal cost and reimbursement issues, and professional and cultural resistance.
CONCLUSIONS: Buprenorphine integration offers a model for other OTPs to facilitate partnerships among primary care and mental health clinics to better serve diverse patients with varying clinical needs and with varying levels of social support.

Entities:  

Keywords:  Buprenorphine treatment; Drug abuse; Opioid treatment program; methadone treatment

Mesh:

Substances:

Year:  2016        PMID: 27745534      PMCID: PMC5540137          DOI: 10.1176/appi.ps.201500501

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  13 in total

1.  Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2006-06

2.  Buprenorphine-naloxone maintenance following release from jail.

Authors:  Joshua D Lee; Ellie Grossman; Andrea Truncali; John Rotrosen; Andrew Rosenblum; Stephen Magura; Marc N Gourevitch
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

3.  Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.

Authors:  Christina M Andrews; Thomas A D'Aunno; Harold A Pollack; Peter D Friedmann
Journal:  Med Care Res Rev       Date:  2013-09-18       Impact factor: 3.929

4.  Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.

Authors:  Brent A Moore; Declan T Barry; Lynn E Sullivan; Patrick G Oʼconnor; Christopher J Cutter; Richard S Schottenfeld; David A Fiellin
Journal:  J Addict Med       Date:  2012-09       Impact factor: 3.702

5.  Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.

Authors:  Wendy Kissin; Caroline McLeod; Joseph Sonnefeld; Arlene Stanton
Journal:  J Addict Dis       Date:  2006

6.  Mobile phone use patterns and preferences in safety net office-based buprenorphine patients.

Authors:  Babak Tofighi; Ellie Grossman; Emily Buirkle; Jennifer McNeely; Marc Gourevitch; Joshua D Lee
Journal:  J Addict Med       Date:  2015 May-Jun       Impact factor: 3.702

7.  Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.

Authors:  Helena B Hansen; Carole E Siegel; Brady G Case; David N Bertollo; Danae DiRocco; Marc Galanter
Journal:  J Behav Health Serv Res       Date:  2013-07       Impact factor: 1.505

Review 8.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

9.  Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services.

Authors:  Susan D Whitley; Hillary V Kunins; Julia H Arnsten; Marc N Gourevitch
Journal:  J Subst Abuse Treat       Date:  2007-01-09

10.  Estimating the prevalence of illicit opioid use in New York City using multiple data sources.

Authors:  Jennifer McNeely; Marc N Gourevitch; Denise Paone; Sharmila Shah; Shana Wright; Daliah Heller
Journal:  BMC Public Health       Date:  2012-06-18       Impact factor: 3.295

View more
  3 in total

1.  The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use.

Authors:  Andrew S Huhn; D Andrew Tompkins; Kelly E Dunn
Journal:  Drug Alcohol Depend       Date:  2017-09-09       Impact factor: 4.492

2.  Prevalence and treatment of opioid use disorders among primary care patients in six health systems.

Authors:  Gwen Lapham; Denise M Boudreau; Eric A Johnson; Jennifer F Bobb; Abigail G Matthews; Jennifer McCormack; David Liu; Jeffrey H Samet; Andrew J Saxon; Cynthia I Campbell; Joseph E Glass; Rebecca C Rossom; Mark T Murphy; Ingrid A Binswanger; Bobbi Jo H Yarborough; Katharine A Bradley
Journal:  Drug Alcohol Depend       Date:  2019-11-15       Impact factor: 4.492

3.  Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.

Authors:  Sugy Choi; Shannon Healy; Liudmila Shapoval; Sarah Forthal; Charles J Neighbors
Journal:  Subst Use Misuse       Date:  2020-12-21       Impact factor: 2.164

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.